Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008-2017.
Adolescent
Adult
Adverse Drug Reaction Reporting Systems
/ statistics & numerical data
Aged
Anticonvulsants
/ adverse effects
Child
Child, Preschool
Databases, Factual
Drug Eruptions
/ epidemiology
Drug Hypersensitivity Syndrome
/ epidemiology
Female
Humans
Infant
Male
Middle Aged
Republic of Korea
Risk Factors
Stevens-Johnson Syndrome
/ epidemiology
Young Adult
Adverse Skin Reactions
Antiepileptic Drugs
KIDS-KAERS
Pharmacovigilance
Journal
Journal of Korean medical science
ISSN: 1598-6357
Titre abrégé: J Korean Med Sci
Pays: Korea (South)
ID NLM: 8703518
Informations de publication
Date de publication:
03 Feb 2020
03 Feb 2020
Historique:
received:
02
11
2019
accepted:
05
12
2019
entrez:
31
1
2020
pubmed:
31
1
2020
medline:
17
3
2020
Statut:
epublish
Résumé
Severe and life-threatening drug eruptions include drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). One class of medications that has been highly associated with such drug eruptions is antiepileptic drugs (AEDs). We attempt to investigate drug eruptions associated with AEDs as a class, as well as with individual AEDs, in Korea. We used the Korea Institute of Drug Safety and Risk Management - Korea Adverse Event Reporting System (KIDS-KAERS) database, a nationwide database of adverse events reports, between January 2008 and December 2017 to investigate the reporting count of all drug eruptions and calculated the ratio of DRESS/SJS/TEN reports for each AED. Among a total of 2,942 reports, most were of rash/urticaria (2,702, 91.8%), followed by those of DRESS (109, 3.7%), SJS (106, 3.6%), and TEN (25, 0.85%). The common causative AEDs were lamotrigine (699, 23.8%), valproic acid (677, 23%), carbamazepine (512, 17.4%), oxcarbazepine (320, 10.9%), levetiracetam (181, 6.2%), and phenytoin (158, 5.4%). In limited to severe drug eruptions (DRESS, SJS, and TEN; total 241 reports), the causative AEDs were carbamazepine (117, 48.8%), lamotrigine (57, 23.8%), valproic acid (20, 8.3%), phenytoin (15, 6.3%), and oxcarbazepine (10, 4.2%). When comparing aromatic AED with non-aromatic AED, aromatic AEDs were more likely to be associated with severe drug eruption (aromatic AEDs: 204/1,793 versus non-aromatic AEDs: 37/1,149; OR, 3.86; 95% CI, 2.7-5.5). Death was reported in 7 cases; DRESS was the most commonly reported adverse event (n = 5), and lamotrigine was the most common causative AED (n = 5). Although most cutaneous drug eruptions in this study were rash or urticaria, approximately 8% of reports were of severe or life-threatening adverse drug reactions, such as SJS, TEN, or DRESS. When hypersensitivity skin reactions occurred, aromatic AEDs were associated with 4 fold the risk of SJS/TEN/DRESS compared with non-aromatic AEDs. Our findings further emphasize that high risk AEDs should be prescribed under careful monitoring, and early detection and prompt interventions are needed to prevent severe complications.
Sections du résumé
BACKGROUND
BACKGROUND
Severe and life-threatening drug eruptions include drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). One class of medications that has been highly associated with such drug eruptions is antiepileptic drugs (AEDs). We attempt to investigate drug eruptions associated with AEDs as a class, as well as with individual AEDs, in Korea.
METHODS
METHODS
We used the Korea Institute of Drug Safety and Risk Management - Korea Adverse Event Reporting System (KIDS-KAERS) database, a nationwide database of adverse events reports, between January 2008 and December 2017 to investigate the reporting count of all drug eruptions and calculated the ratio of DRESS/SJS/TEN reports for each AED.
RESULTS
RESULTS
Among a total of 2,942 reports, most were of rash/urticaria (2,702, 91.8%), followed by those of DRESS (109, 3.7%), SJS (106, 3.6%), and TEN (25, 0.85%). The common causative AEDs were lamotrigine (699, 23.8%), valproic acid (677, 23%), carbamazepine (512, 17.4%), oxcarbazepine (320, 10.9%), levetiracetam (181, 6.2%), and phenytoin (158, 5.4%). In limited to severe drug eruptions (DRESS, SJS, and TEN; total 241 reports), the causative AEDs were carbamazepine (117, 48.8%), lamotrigine (57, 23.8%), valproic acid (20, 8.3%), phenytoin (15, 6.3%), and oxcarbazepine (10, 4.2%). When comparing aromatic AED with non-aromatic AED, aromatic AEDs were more likely to be associated with severe drug eruption (aromatic AEDs: 204/1,793 versus non-aromatic AEDs: 37/1,149; OR, 3.86; 95% CI, 2.7-5.5). Death was reported in 7 cases; DRESS was the most commonly reported adverse event (n = 5), and lamotrigine was the most common causative AED (n = 5).
CONCLUSION
CONCLUSIONS
Although most cutaneous drug eruptions in this study were rash or urticaria, approximately 8% of reports were of severe or life-threatening adverse drug reactions, such as SJS, TEN, or DRESS. When hypersensitivity skin reactions occurred, aromatic AEDs were associated with 4 fold the risk of SJS/TEN/DRESS compared with non-aromatic AEDs. Our findings further emphasize that high risk AEDs should be prescribed under careful monitoring, and early detection and prompt interventions are needed to prevent severe complications.
Identifiants
pubmed: 31997613
pii: 35.e17
doi: 10.3346/jkms.2020.35.e17
pmc: PMC6995813
doi:
Substances chimiques
Anticonvulsants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e17Informations de copyright
© 2020 The Korean Academy of Medical Sciences.
Déclaration de conflit d'intérêts
The authors have no potential conflicts of interest to disclose.
Références
J Korean Med Sci. 2012 Mar;27(3):285-90
pubmed: 22379340
Continuum (Minneap Minn). 2010 Jun;16(3 Epilepsy):136-58
pubmed: 22810319
Pharmacol Rep. 2015 Jun;67(3):426-34
pubmed: 25933949
Lancet Neurol. 2012 Sep;11(9):792-802
pubmed: 22832500
Epilepsia Open. 2017 Apr 28;2(2):273-275
pubmed: 29588957
Cochrane Database Syst Rev. 2011 Oct 05;(10):CD009183
pubmed: 21975791
Neurologia. 2018 Apr;33(3):165-176
pubmed: 25976948
Continuum (Minneap Minn). 2019 Apr;25(2):343-361
pubmed: 30921013
Clin Pharmacol Ther. 2015 May;97(5):508-17
pubmed: 25670505
Nature. 2004 Apr 1;428(6982):486
pubmed: 15057820
Allergy Asthma Immunol Res. 2019 Mar;11(2):231-240
pubmed: 30661315
Br J Clin Pharmacol. 2017 Feb;83(2):227-246
pubmed: 27558545
Epilepsy Behav. 2005 May;6(3):382-7
pubmed: 15820347
Eur Rev Med Pharmacol Sci. 2015;19(14):2732-7
pubmed: 26221907
Eur J Intern Med. 2018 Jul;53:40-44
pubmed: 29409745
Drug Saf. 2008;31(8):695-702
pubmed: 18636788
HLA. 2019 Jun;93(6):417-435
pubmed: 30895730
Epilepsy Res. 2011 May;94(3):213-7
pubmed: 21377329
Neurology. 2007 May 15;68(20):1701-9
pubmed: 17502552
J Allergy Clin Immunol Pract. 2018 Nov - Dec;6(6):2043-2050
pubmed: 29501520
Clin Drug Investig. 2019 Apr;39(4):363-368
pubmed: 30689189
Allergy Asthma Immunol Res. 2019 Sep;11(5):709-722
pubmed: 31332981
Lancet. 2000 Oct 7;356(9237):1255-9
pubmed: 11072960
Epilepsia. 2018 Dec;59(12):2318-2324
pubmed: 30395352
An Bras Dermatol. 2017 May-Jun;92(3):345-349
pubmed: 29186246
J Korean Med Sci. 2016 Sep;31(9):1355-61
pubmed: 27510377
J Pharm Pract. 2012 Apr;25(2):142-50
pubmed: 22095580